471 related articles for article (PubMed ID: 15755632)
1. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM
Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632
[TBL] [Abstract][Full Text] [Related]
2. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
Vermorken JB; Claessen AM; van Tinteren H; Gall HE; Ezinga R; Meijer S; Scheper RJ; Meijer CJ; Bloemena E; Ransom JH; Hanna MG; Pinedo HM
Lancet; 1999 Jan; 353(9150):345-50. PubMed ID: 9950438
[TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.
Harris JE; Ryan L; Hoover HC; Stuart RK; Oken MM; Benson AB; Mansour E; Haller DG; Manola J; Hanna MG
J Clin Oncol; 2000 Jan; 18(1):148-57. PubMed ID: 10623705
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
Smith RE; Colangelo L; Wieand HS; Begovic M; Wolmark N
J Natl Cancer Inst; 2004 Aug; 96(15):1128-32. PubMed ID: 15292384
[TBL] [Abstract][Full Text] [Related]
6. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
7. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
de Weger VA; Turksma AW; Voorham QJ; Euler Z; Bril H; van den Eertwegh AJ; Bloemena E; Pinedo HM; Vermorken JB; van Tinteren H; Meijer GA; Hooijberg E
Clin Cancer Res; 2012 Feb; 18(3):882-9. PubMed ID: 22156611
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
[TBL] [Abstract][Full Text] [Related]
10. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
12. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
[TBL] [Abstract][Full Text] [Related]
13. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
[TBL] [Abstract][Full Text] [Related]
14. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Meyerhardt JA; Heseltine D; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Thomas J; Nelson H; Whittom R; Hantel A; Schilsky RL; Fuchs CS
J Clin Oncol; 2006 Aug; 24(22):3535-41. PubMed ID: 16822843
[TBL] [Abstract][Full Text] [Related]
15. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report.
Tominaga T; Sakabe T; Koyama Y; Hamano K; Yasutomi M; Takahashi T; Kodaira S; Kato T; Ogawa N
Cancer; 1996 Aug; 78(3):403-8. PubMed ID: 8697383
[TBL] [Abstract][Full Text] [Related]
18. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study.
Ahmed S; Ahmad I; Zhu T; Arnold FP; Faiz Anan G; Sami A; Yadav SK; Alvi R; Haider K
Dis Colon Rectum; 2010 Oct; 53(10):1432-8. PubMed ID: 20847626
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis.
Repmann R; Goldschmidt AJ; Richter A
Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332
[TBL] [Abstract][Full Text] [Related]
20. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
Koperna T; Semmler D
Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
